Skip to main content
MMedVellum
MCQsExamsAtlas
DashboardPricing
MMedVellum

The exam atlas that feels like a flagship product — evidence-graded topics and exam tools for MBBS and fellowship preparation. Built to scale to fifty specialties. Educational content only — not medical advice.

llms.txt·psychiatry LLM catalog · sitemap

Atlas

  • Specialty atlas
  • MBBS / Core medicine
  • Dermatology
  • ICU Fellowship (CICM)
  • Anaesthesia
  • Emergency Medicine
  • Psychiatry Fellowship

Study & account

  • MCQ practice
  • Practice alias
  • Exam tools
  • Dashboard
  • Pricing
  • Sign in

© 2026 MedVellum. For education only — not a substitute for clinical judgement.

Clinical Atlas Prestige · Evidence-first

Psych VivasSpecialty psychiatry — sexual medicine interface

Psych Vivas · Specialty psychiatry — sexual medicine interface

Erectile and ejaculatory disorders — structured clinical viva

Fellowship viva spanning PDE5 use conditions, lifelong PE, SSRI sexual effects, and couple-informed care.

clinical
On this page & tools

Target exams

FRANZCPMRCPsychABPNMD-DNB

Target exams

FRANZCPMRCPsychABPNMD-DNB
Prompt
You are the psychiatry registrar. A urology colleague asks you to co-manage a 41-year-old man referred after two failed sildenafil trials. History reveals: (1) sildenafil taken without sexual stimulation while intoxicated with alcohol; (2) lifelong PE with IELT under 1 minute and severe shame; (3) recent escitalopram 20 mg for panic with new delayed orgasm on masturbation but partner intercourse still early because of PE anxiety; (4) partner threatening separation. Discuss mechanisms, assessment, and an integrated management plan including when PDE5i 'failure' is not pharmacological failure.

Interpretation

Reveal interpretation

PDE5i "failure." Sildenafil requires sexual stimulation to work (NO–cGMP pathway) and is undermined by heavy alcohol, incorrect timing, and performance anxiety/high sexual inhibition. Re-education, alcohol reduction, and adequate trial conditions often convert "non-responders" into responders; true non-response prompts medical review and second-line urology options, not automatic prosthesis talk on visit one.[1][4][6]

Lifelong PE. Short IELT from early sexual life plus inability to delay and distress meets ISSM-style lifelong PE. Behavioural techniques and PE-directed pharmacotherapy (daily SSRI strategies or dapoxetine where licensed) are evidence-aligned; couple therapy addresses separation threat.[2][5]

Escitalopram paradox. SSRIs delay orgasm/ejaculation (useful for PE, harmful as an unplanned side-effect). Here masturbation is delayed but partnered PE persists — anxiety, rushing, and relationship threat maintain short partnered latency. Do not assume the SSRI has "fixed" PE; integrate behavioural PE work and consider whether panic regimen can be optimised without abandoning anxiety control.[3][2]

Integrated plan. (1) Medical suitability and nitrate check before any further PDE5i; teach correct use. (2) Alcohol counselling. (3) PE behavioural package and consider dedicated PE pharmacology if needed after clarifying the SSRI plan. (4) Panic/depression monitoring if changing serotonergic agents. (5) Couple session for shame and separation crisis. (6) Safety-net suicidality if separation proceeds.[2][3][6]

Key points

PDE5i conditions

Needs stimulation; alcohol and anxiety sabotage trials.

Lifelong PE

Latency + control + distress — behavioural ± SSRI/dapoxetine.

SSRI double edge

Delays ejaculation but is not automatic PE cure in anxious partnered sex.
[1] [2] [3]

References

  1. [1]Goldstein I, Lue TF, Padma-Nathan H, et al. Oral sildenafil in the treatment of erectile dysfunction. Sildenafil Study Group N Engl J Med, 1998.PMID 9580646
  2. [2]Althof SE, McMahon CG, Waldinger MD, et al. An update of the International Society of Sexual Medicine's guidelines for the diagnosis and treatment of premature ejaculation (PE) J Sex Med, 2014.PMID 24848686
  3. [3]Montejo AL, Llorca G, Izquierdo JA, et al. Incidence of sexual dysfunction associated with antidepressant agents: a prospective multicenter study of 1022 outpatients J Clin Psychiatry, 2001.PMID 11229449
  4. [4]Bancroft J, Graham CA, Janssen E, Sanders SA The dual control model: current status and future directions J Sex Res, 2009.PMID 19308839
  5. [5]Pryor JL, Althof SE, Steidle C, et al. Efficacy and tolerability of dapoxetine in treatment of premature ejaculation: an integrated analysis of two double-blind, randomised controlled trials Lancet, 2006.PMID 16962882
  6. [6]Burnett AL, Nehra A, Breau RH, et al. Erectile Dysfunction: AUA Guideline J Urol, 2018.PMID 29746858